• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announces Received Approval of Insulin Glargine Products in Malaysia
    Gan & Lee Pharmaceuticals Announces Received Approval of Insulin Glargine Products in Malaysia
    Date:2025-02-14

    Beijing, China, Recently– Gan & Lee Pharmaceuticals, a leading global biopharmaceutical company (hereinafter referred to as Gan & Lee, stock code: 603087.SH),announced that its insulin glargine injection and insulin glargine prefilled pen products, developed in collaboration with a major Malaysian pharmaceutical company in Malaysia, have received registration approval from the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. This approval marks the first time Gan & Lee’s insulin products have entered the Malaysian market and serves as a significant milestone in the company’s internationalization strategy, laying a solid foundation for future expansion in the Southeast Asian market.

     

    Malaysia, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), maintains a stringent drug regulatory system. Gan & Lee’s insulin glargine products, bolstered by their impressive clinical trial data from Europe and the United States, have successfully passed NPRA’s rigorous review process. These products, encompassing comprehensive preclinical pharmacological characteristics, PK/PD profiles, and immunogenicity features, align closely with the reference drug Lantus? in terms of quality. This achievement highlights Gan & Lee robust capabilities in quality control and its prowess in international regulatory affairs.

     

    As a key economic hub in Southeast Asia, Malaysia faces a high prevalence rate of diabetes. According to the International Diabetes Federation (IDF) 2021 report, the prevalence of diabetes among individuals aged 20 to 79 in the country stands at 20%, affecting approximately 4.43 million people. The approval of insulin glargine products in Malaysia, compared to second-generation insulin, demonstrates significant clinical advantages, including more stable and long-lasting blood glucose control, as well as a lower incidence of adverse reactions. The introduction of these products will not only improve access to medication and treatment adherence for local diabetes patients but also optimize the overall healthcare resource allocation for diabetes management, better addressing the growing healthcare needs of the local population.

     

    As a leading biopharmaceutical company in China, Gan & Lee has been actively responding to the “Belt and Road” Initiative, aiming to share development opportunities with countries and regions along the “Belt and Road”. To date, the company has established stable partnerships in over 20 countries and regions, including India, Pakistan, and Kazakhstan, providing high-quality treatment solutions for diabetes patients worldwide. The breakthrough in the Malaysian market not only strengthens the deep cooperation between the two companies in production and distribution but also contributes positively to the health and well-being of the Malaysian population. Moving forward, Gan & Lee will continue to uphold the spirit of the “Belt and Road” Initiative, working hand in hand with global partners to provide better, more accessible medicines and services for patients worldwide, contributing to the establishment of a global health community.

     

    References:

    1. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/data/en/country/120/my.html


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號(hào)-1 | 京公網(wǎng)安備 11011202003900號(hào)
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产ts人妖系列视频网站| 日韩欧美中文字幕出| 国产的一级毛片完整| 久久婷婷国产综合精品| 色一乱一伦一区一直爽| 好紧好大好爽14p| 亚洲码欧美码一区二区三区| 一本大道在线无码一区| 老子影院我不卡在线理论| 日本午夜精品一区二区三区电影| 国产欧美日韩精品丝袜高跟鞋| 久久天天躁狠狠躁夜夜躁综合| 美国美女一级毛片免费全| 夜色私人影院永久入口| 亚洲人成人网站在线观看| 被猛男cao男男粗大视频| 无码一区二区三区中文字幕| 体育生开房互操| 中文字幕日韩丝袜一区| 欧洲精品免费一区二区三区| 国产精品揄拍一区二区| 久久大香香蕉国产| 真实国产乱子伦高清| 国产精品无码一区二区三区不卡| 久久精品99国产精品日本| 精品91自产拍在线| 国产精品乱码在线观看| 中文字幕视频网站| 毛片无码免费无码播放| 国内精品久久久久影院一蜜桃 | 国产偷亚洲偷欧美偷精品| 久久国产精品免费专区| 第一福利官方导航| 国产精品久久久久影院嫩草| 中文字幕国产视频| 欧美疯狂xxxx乱大交视频| 国产亚洲成AV人片在线观看| 99国产成+人+综合+亚洲欧美| 日韩精品无码久久一区二区三| 国产午夜精品一二区理论影院| www.亚洲精品|